Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children

Vaccine

Volumn 31, Issue 4, 2013, Pages 647-652

  Saha, Amit ^a   Chowdhury, Mohiul I ^a   Nazim, Mohammad ^a   Alam, Mohammad Murshid ^a   Ahmed, Tanvir ^c   Hossain, Mohammad Bakhtiar ^a   Hore, Samar Kumar ^a   Sultana, Gazi Nurun Nahar ^d   Svennerholm, Ann Mari ^b   Qadri, Firdausi ^a  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Variation Biotechnologies Inc   (Canada)

^d UNIVERSITY OF DHAKA   (Bangladesh)

Author keywords

Arsenic; Complement factors C3 and C4; Dukoral; EPI vaccines; Immunogenicity

Indexed keywords

ARSENIC; CHOLERA VACCINE; DIPHTHERIA TETANUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MEASLES VACCINE;

ANTIBODY RESPONSE; ARSENIC POISONING; ARTICLE; BANGLADESH; CHILD; CHOLERA; DIPHTHERIA; EXPANDED PROGRAM ON IMMUNIZATION; FEMALE; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MEASLES; PRESCHOOL CHILD; PRIORITY JOURNAL; TETANUS; URINALYSIS;

ADMINISTRATION, ORAL; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ARSENIC; BANGLADESH; CHILD, PRESCHOOL; CHOLERA; CHOLERA TOXIN; CHOLERA VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; MEASLES VACCINE; TREATMENT OUTCOME; VACCINES, INACTIVATED;

EID: 84871937234     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.049     Document Type: Article

References (46)

1. BBS. Bangladesh Bureau of Statistics 1999, Statistical Year Book of Bangladesh, Dhaka, Bangladesh; 2001.
2. Sack D.A., Qadri F., Svennerholm A.M. Determinants of responses to oral vaccines in developing countries. Ann Nestle 2008, 66:71-79.
3. Clemens J.D., Sack D.A., Chakraborty J., Rao M.R., Ahmed F., Harris J.R., et al. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. Vaccine 1990, 8(5):469-472.
4. Qadri F., Ahmed T., Ahmed F., et al. Mucosal and systemic immune responses in patients with diarrhea due to CS6-expressing enterotoxigenic Escherichia coli. Infect Immun 2007, 75:2269-2274.
5. Rennels M.B. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis 1996, 174(Suppl. 1):S107-S111.
6. Simanjuntak M.T., Sato H., Tamai I., Terasaki T., Tsuji A. Transport of the new quinolone antibacterial agents of lomefloxacin and ofloxacin by rat erythrocytes, and its relation to the nicotinic acid transport system. J Pharmacobiodyn 1991, 14:475-481.
7. Ahmed T., Svennerholm A.M., Al Tarique A., Sultana G.N., Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine 2009, 27:1433-1439.
8. Ahren C., Jertborn M., Svennerholm A.M. Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood. Infect Immun 1998, 66:3311-3316.
9. McVernon J., Andrews N., Slack M., Moxon R., Ramsay M. Host and environmental factors associated with Hib in England, 1998-2002. Arch Dis Child 2008, 93:670-675.
10. Vahter M., Concha G., Nermell B., Nilsson R., Dulout F., Natarajan A.T. A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol 1995, 293:455-462.
11. Lemarie A., Morzadec C., Bourdonnay E., Fardel O., Vernhet L. Human macrophages constitute targets for immunotoxic inorganic arsenic. J Immunol 2006, 177:3019-3027.
12. Lemarie A., Morzadec C., Merino D., Micheau O., Fardel O., Vernhet L. Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB-related survival pathway down-regulation. J Pharmacol Exp Ther 2006, 316:304-314.
13. Conde P., Acosta-Saavedra L.C., Goytia-Acevedo R.C., Calderon-Aranda E.S. Sodium arsenite-induced inhibition of cell proliferation is related to inhibition of IL-2 mRNA expression in mouse activated T cells. Arch Toxicol 2007, 81:251-259.
14. Galicia G., Leyva R., Tenorio E.P., Ostrosky-Wegman P., Saavedra R. Sodium arsenite retards proliferation of PHA-activated T cells by delaying the production and secretion of IL-2. Int Immunopharmacol 2003, 3:671-682.
15. Sikorski E.E., Burns L.A., McCoy K.L., Stern M., Munson A.E. Suppression of splenic accessory cell function in mice exposed to gallium arsenide. Toxicol Appl Pharmacol 1991, 110:143-156.
16. Soto-Pena G.A., Luna A.L., Acosta-Saavedra L., Conde P., Lopez-Carrillo L., Cebrian M.E., et al. Assessment of lymphocyte subpopulations and cytokine secretion in children exposed to arsenic. FASEB J 2006, 20(6):779-781.
17. Sengupta M., Bishayi B. Effect of lead and arsenic on murine macrophage response. Drug Chem Toxicol 2002, 25:459-472.
18. Islam L.N., Nabi A.H., Rahman M.M., Zahid M.S. Association of respiratory complications and elevated serum immunoglobulins with drinking water arsenic toxicity in human. J Environ Sci Health A: Tox Hazard Subst Environ Eng 2007, 42:1807-1814.
19. Yoshida T., Shimamura T., Shigeta S. Enhancement of the immune response in vitro by arsenic. Int J Immunopharmacol 1987, 9:411-415.
20. WHO/Unicef. Diphtheria-tetanus-pertusis (DTP3) immunization coverage Global and by WHO region, 1980-2010; 2011.
21. Qadri F., Chowdhury M.I., Faruque S.M., Salam M.A., Ahmed T., Begum Y.A., et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007, 25(2):231-238.
22. Saha A., Chowdhury M.I., Khanam F., Bhuiyan M.S., Chowdhury F., Khan A.I., et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 2011, 29(46):8285-8292.
23. NAISU. An overview of arsenic issues and mitigation initiatives in Bangladesh; 2003.
24. Jertborn M., Svennerholm A.M., Holmgren J. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 1992, 10:130-132.
25. Qadri F., Mohi G., Hossain J., Azim T., Khan A.M., Salam M.A., et al. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin Diagn Lab Immunol 1995, 2(6):685-688.
26. Qadri F., Khan A.I., Faruque A.S., Begum Y.A., Chowdhury F., Nair G.B., et al. Enterotoxigenic Escherichia coli and Vibrio cholerae diarrhea Bangladesh, 2004. Emerg Infect Dis 2005, 11(7):1104-1107.
27. Qadri F., Wenneras C., Albert M.J., Hossain J., Mannoor K., Begum Y.A., et al. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect Immun 1997, 65(9):3571-3576.
28. Alam M.M., Riyadh M.A., Fatema K., Rahman M.A., Akhtar N., Ahmed T., et al. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin Vaccine Immunol 2011, 18(5):844-850.
29. Calderon R.L., Hudgens E., Le X.C., Schreinemachers D., Thomas D.J. Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ Health Perspect 1999, 107:663-667.
30. Hwang Y.H., Grote B.R., Menrath J., Roda W.S. Urinary arsenic excretion as a biomarker of arsenic exposure in children. Arch Environ Health 1997, 52:139-147.
31. Rahman A., Vahter M., Ekstrom E.C., Persson L.A. Arsenic exposure in pregnancy increases the risk of lower respiratory tract infection and diarrhea during infancy in Bangladesh. Environ Health Perspect 2011, 119:719-724.
32. Buchet J.P., Staessen J., Roels H., Lauwerys R., Fagard R. Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study. Occup Environ Med 1996, 53:320-327.
33. Kristiansen J., Christensen J.M., Iversen B.S., Sabbioni E. Toxic trace element reference levels in blood and urine: influence of gender and lifestyle factors. Sci Total Environ 1997, 204:147-160.
34. Trepka M.J., Heinrich J., Schulz C., Krause C., Popescu M., Wjst M., et al. Arsenic burden among children in industrial areas of eastern Germany. Sci Total Environ 1996, 180(2):95-105.
35. Yamauchi H., Takahashi K., Mashiko M., Yamamura Y. Biological monitoring of arsenic exposure of gallium arsenide- and inorganic arsenic-exposed workers by determination of inorganic arsenic and its metabolites in urine and hair. Am Ind Hyg Assoc J 1989, 50:606-612.
36. Andrew A.S., Jewell D.A., Mason R.A., Whitfield M.L., Moore J.H., Karagas M.R. Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect 2008, 116:524-531.
37. WHO. Weekly epidemiological record, WHO position paper; 2011.
38. Islam L.N., Nabi A.H., Rahman M.M., Khan M.A., Kazi A.I. Association of clinical complications with nutritional status and the prevalence of leukopenia among arsenic patients in Bangladesh. Int J Environ Res Public Health 2004, 1:74-82.
39. Arifuzzaman M., Rashu R., Leung D.T., Hosen M.I., Bhuiyan T.R., Bhuiyan M.S., et al. Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison with natural cholera. Clin Vaccine Immunol 2012, 19:1304-1311.
40. Qadri F., Bhuiyan T.R., Dutta K.K., Raqib R., Alam M.S., Alam N.H., et al. Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut. Gut 2004, 53(1):62-69.
41. Albert M.J., Qadri F., Wahed M.A., Ahmed T., Rahman A.S., Ahmed F., et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J Infect Dis 2003, 187(6):909-913.
42. Arguelles M.H., Orellana M.L., Castello A.A., Villegas G.A., Masini M., Belizan A.L., et al. Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine. J Clin Microbiol 2006, 44(8):2733-2738.
43. Kirmani K.I., Lofthus G., Pichichero M.E., Voloshen T., D'Angio C.T. Seven-year follow-up of vaccine response in extremely premature infants. Pediatrics 2002, 109:498-504.
44. Vesikari T., Joensuu J., Baer M., Kayhty H., Olander R.M., Sormunen H., et al. Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines. Acta Paediatr 1999, 88(5):513-520.
45. Dunkelberger J.X., Song W.Y. Complement and its role in innate and adaptive immune responses. Cell Res 2010, 34-50.
46. Fan X., Ling Y., Wu Y., Hou J. Relationship between complement activation and reactive oxygen species generation in inflammatory response. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1999, 21:170-174.